Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

Presentation TCT 2017

DECISION-CTO and EURO-CTO: Critique and Unanswered Questions

Presenter: David J. Cohen, Ajay J. Kirtane, Emmanouil S. Brilakis

November 01, 2017

Presentation TCT 2017

DECISION-CTO and EURO-CTO: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Gerald S. Werner

November 01, 2017

Presentation TCT 2017

AIDA: Critique and Unanswered Questions

Presenter: David J. Cohen, Ajay J. Kirtane, Debabrata Mukherjee

November 01, 2017

Presentation TCT 2017

AIDA: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Jose P.S. Henriques

November 01, 2017

Presentation TCT 2017

DEFINE FLAIR/SWEDEHEART: Critique and Unanswered Questions

Presenter: David J. Cohen, Ajay J. Kirtane, Habib Samady

November 01, 2017

Presentation TCT 2017

DEFINE FLAIR/SWEDEHEART: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Thomas Engstroem

November 01, 2017

Presentation TCT 2017

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Presenter: Alfredo Trento, David J. Cohen

November 01, 2017

Presentation TCT 2017

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

Presenter: Bernard Prendergast, Brian K. Whisenant, David J. Cohen

November 01, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Presenter: Mauricio G. Cohen, Simon R. Dixon, David Daniels

October 30, 2017

Presentation TVT 2017

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Presenter: David J. Cohen, Jeffrey J. Popma, Robert O. Bonow

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Philippe Généreux

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: David J. Cohen, Jeffrey J. Popma, Nicolas M. Van Mieghem

June 16, 2017

Presentation TVT 2017

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

Presenter: David J. Cohen, Jeffrey J. Popma, Howard C. Herrmann

June 16, 2017

Presentation TVT 2017

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

Presenter: David J. Cohen, Jeffrey J. Popma, Martin B. Leon

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Advertisement

DECISION-CTO and EURO-CTO: Critique and Unanswered Questions

DECISION-CTO and EURO-CTO: Topline Findings and Practice Implications

AIDA: Critique and Unanswered Questions

AIDA: Topline Findings and Practice Implications

DEFINE FLAIR/SWEDEHEART: Critique and Unanswered Questions

DEFINE FLAIR/SWEDEHEART: Topline Findings and Practice Implications

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content